Neuroscientific Biopharmaceuticals Ltd. (AU:NSB)
ASX:NSB
Want to see AU:NSB full AI Analyst Report?
NSB Stock Chart & Stats
AU$0.10
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.10
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.05 - AU$0.26
Previous CloseN/A
Volume70.60K
Average Volume (3M)306.60K
Market Cap
AU$32.92M
Enterprise ValueAU$31.82M
Total Cash (Recent Filing)AU$7.27M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding332,575,700
10 Day Avg. Volume291,172
30 Day Avg. Volume306,603
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.76
Price to Sales (P/S)0.00
P/FCF Ratio-13.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero reported debt materially reduces solvency risk and interest burden, giving management flexibility to fund R&D or raise dilutive equity on better terms. Over 2–6 months a debt-free structure supports operational continuity while development milestones are pursued.
Focused Neuroscience R&D ModelA clear strategic focus on neuroscience concentrates resources on a high-barrier therapeutic area where successful assets can command premium pricing and partnership interest. Structurally, this specialization can attract collaborators and long-term licensing deals if clinical progress is demonstrated.
Intermittent Operational Upside (2024)Achieving a modest net profit and positive cash flow in 2024 shows the business can deliver operational improvements and momentary commercial or cost efficiencies. If management replicates those levers, it evidences the potential to narrow losses over the medium term.
Bears Say
Revenue Collapse And VolatilityA drop to zero annual revenue in 2025 indicates weak or non-recurring commercial traction, reducing predictability of cash inflows. For a development-stage biotech, prolonged revenue absence increases reliance on external funding and slows de-risking of the business model.
Persistent Cash BurnConsistent negative operating and free cash flows point to ongoing funding needs. Over several months this elevates dilution or financing risk, forcing management to seek capital or partnerships which can constrain strategic choices and shareholder value capture.
Recurring Operating LossesSustained operating losses and mostly negative returns on equity show limited current capacity to generate shareholder returns. Without durable revenue or margin improvement, persistent losses undermine long-term value creation and heighten dependence on external funding.
Neuroscientific Biopharmaceuticals Ltd. News
NSB FAQ
What was Neuroscientific Biopharmaceuticals Ltd.’s price range in the past 12 months?
Neuroscientific Biopharmaceuticals Ltd. lowest share price was AU$0.05 and its highest was AU$0.26 in the past 12 months.
What is Neuroscientific Biopharmaceuticals Ltd.’s market cap?
Neuroscientific Biopharmaceuticals Ltd.’s market cap is AU$32.92M.
When is Neuroscientific Biopharmaceuticals Ltd.’s upcoming earnings report date?
Neuroscientific Biopharmaceuticals Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 102 days.
How were Neuroscientific Biopharmaceuticals Ltd.’s earnings last quarter?
Neuroscientific Biopharmaceuticals Ltd. released its earnings results on Feb 25, 2026. The company reported -AU$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.005.
Is Neuroscientific Biopharmaceuticals Ltd. overvalued?
According to Wall Street analysts Neuroscientific Biopharmaceuticals Ltd.’s price is currently Overvalued.
Does Neuroscientific Biopharmaceuticals Ltd. pay dividends?
Neuroscientific Biopharmaceuticals Ltd. does not currently pay dividends.
What is Neuroscientific Biopharmaceuticals Ltd.’s EPS estimate?
Neuroscientific Biopharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Neuroscientific Biopharmaceuticals Ltd. have?
Neuroscientific Biopharmaceuticals Ltd. has 332,575,700 shares outstanding.
What happened to Neuroscientific Biopharmaceuticals Ltd.’s price movement after its last earnings report?
Neuroscientific Biopharmaceuticals Ltd. reported an EPS of -AU$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Neuroscientific Biopharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in AU:NSB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neuroscientific Biopharmaceuticals Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
265.85%
12-Months-Change
Fundamentals
Return on Equity
-19.10%
Trailing 12-Months
Asset Growth
232.64%
Trailing 12-Months
Company Description
Neuroscientific Biopharmaceuticals Ltd.
NeuroScientific Biopharmaceuticals Limited develops therapeutic treatments for neurodegenerative diseases through preclinical and clinical studies of patented technologies. Its lead drug candidates include EmtinB for treatment of neurodegenerative dementia and Alzheimer's disease, and degenerative conditions of the optic nerve. The company was incorporated in 2002 and is based in Cottesloe, Australia.
Technical Analysis
Cynata Therapeutics Limited
―
Prescient Therapeutics Limited
―
Starpharma Holdings Limited
―
Island Pharmaceuticals Ltd
―
AnteoTech Ltd
―
Options Prices
Currently, No data available
---